Some are predicting that GLP-1s could pose a disruptive threat to the medtech industry, as demand for medical devices and surgical procedures could be greatly reduced.
2024-07-24 13:44
Taymour Tamaddon, Portfolio Manager, US Large Cap Growth Equity Strategy
Key Insights
While GLP‑1s have been around almost 20 years, they’ve recently been catapulted into the public domain due to their demonstrated effectiveness as a weight loss agent.
This success has led to speculation about broader impacts on the medtech industry, given its principal role in the treatment and management of obesity and its comorbidities.
Some are predicting that GLP‑1s pose a disruptive threat to the medtech industry, as demand for medical devices and surgical procedures could be greatly reduced.
Do you want to go directly to the Financial Advisors/Intermediaries site when you visit troweprice.com?
Confirm
You are currently logged in to multiple T. Rowe Price websites.
You will need to log out below and log back in with your Advisor Dashboard credentials.
Log Out Now
You are now leaving the T. Rowe Price website.
T. Rowe Price is not responsible for the content of third party websites, including any performance data contained within them. Past performance cannot guarantee future results.